Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab in Prodromal Alzheimer's Disease
NCT02760602Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jun 2016; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02760602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760602.